SCHEMBL3755753

SCHEMBL3755753

O=C(O)CNC(=O)c1c(O)c(-c2ccccn2)cc2nc(-c3ccccc3)cnc12

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EGLN3 Q9H6Z9 5/20 0.59
EGLN1 Q9GZT9 9/20 0.43
FTO Q9C0B1 4/20 0.43
KDM5B Q9UGL1 2/20 0.43
KDM2A Q9Y2K7 2/20 0.43
ABL1 P00519 1/20 0.41
KDM6B O15054 1/20 0.40
KDM4C Q9H3R0 1/20 0.40
KDM3A Q9Y4C1 1/20 0.40
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
DHODH Q02127 1/20 0.40
NPC1 O15118 1/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
HTT P42858 1/20 0.39
RAB9A P51151 1/20 0.39
EGLN2 Q96KS0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3520126 0.92 EGLN3 (0.62) EGLN3EGLN1FTOKDM5BKDM2A
SCHEMBL3520368 0.92 EGLN3 (0.64) EGLN3EGLN1FTOKDM5BKDM2A
SCHEMBL3524105 0.89 LMNA (0.49) EGLN3ABL1KDM4EALDH1A1NPC1
SCHEMBL3525060 0.86 DHODH (0.45) EGLN3KDM2AABL1KDM6BKDM4C
SCHEMBL3763139 0.85 EGLN3 (0.54) EGLN3EGLN1FTOKDM5BKDM2A
SCHEMBL3766921 0.85 EGLN3 (0.69) EGLN3EGLN1FTOKDM5BKDM2A
SCHEMBL3522312 0.83 EGLN3 (0.67) EGLN3EGLN1FTOKDM5BKDM2A
SCHEMBL3756929 0.82 EGLN3 (0.53) EGLN3EGLN1FTOKDM4EALDH1A1
SCHEMBL3756186 0.81 EGLN3 (0.50) EGLN3ABL1KDM4EALDH1A1NPC1
SCHEMBL3519887 0.79 EGLN3 (0.66) EGLN3EGLN1FTOKDM5BKDM2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US claimed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 EGLN3 2/4885EGLN1 6/4885FTO 741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.